A detailed history of Jane Street Group, LLC transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Jane Street Group, LLC holds 214,635 shares of MREO stock, worth $768,393. This represents 0.0% of its overall portfolio holdings.

Number of Shares
214,635
Previous 84,593 153.73%
Holding current value
$768,393
Previous $304,000 190.13%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.45 - $4.87 $448,644 - $633,304
130,042 Added 153.73%
214,635 $882,000
Q2 2024

Aug 14, 2024

SELL
$2.58 - $4.25 $5,882 - $9,690
-2,280 Reduced 2.62%
84,593 $304,000
Q1 2024

May 15, 2024

BUY
$2.3 - $4.05 $199,807 - $351,835
86,873 New
86,873 $286,000
Q3 2023

Nov 14, 2023

SELL
$1.15 - $1.67 $1,680 - $2,439
-1,461 Reduced 7.79%
17,285 $22,000
Q2 2023

Aug 14, 2023

SELL
$0.79 - $1.43 $57,154 - $103,456
-72,347 Reduced 79.42%
18,746 $24,000
Q1 2023

May 15, 2023

SELL
$0.71 - $1.22 $72,326 - $124,280
-101,869 Reduced 52.79%
91,093 $64,000
Q4 2022

Feb 14, 2023

BUY
$0.5 - $1.01 $9,588 - $19,367
19,176 Added 11.03%
192,962 $144,000
Q3 2022

Nov 14, 2022

BUY
$0.82 - $1.73 $124,444 - $262,548
151,762 Added 689.08%
173,786 $150,000
Q2 2022

Aug 16, 2022

BUY
$0.33 - $1.69 $7,267 - $37,220
22,024 New
22,024 $25,000
Q2 2021

Aug 16, 2021

SELL
$2.94 - $4.08 $138,823 - $192,653
-47,219 Closed
0 $0
Q1 2021

May 18, 2021

BUY
$2.6 - $4.43 $62,870 - $107,121
24,181 Added 104.96%
47,219 $159,000
Q4 2020

Feb 17, 2021

BUY
$1.95 - $3.6 $44,924 - $82,936
23,038 New
23,038 $82,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $447M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.